Chiesi Famaceutici SpA, of Parma, Italy, said the European Commission approved Holoclar, a medicine containing stem cells to treat a rare condition caused by burns to the eye, specifically limbal stem cell deficiency due to physical or chemical burns, which can cause blindness if untreated. The EMA issued a positive recommendation on the therapy in December.